You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High risk of recurrence

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-clear Renal Cell Carcinoma Trial in Nanjing, Nanning (Toripalimab, Axitinib)

Recruiting
  • Non-clear Renal Cell Carcinoma
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

Hepatocellular Carcinoma Trial (Donafenib + Tislelizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Donafenib + Tislelizumab
  • (no location specified)
Sep 15, 2022

Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

Not yet recruiting
  • Liver Transplant; Complications
  • +3 more
  • multi-kinase inhibitors in combination with bevacizumab
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

Radiotherapy, Immunotherapy, Liver Metastases Trial in Shanghai (SBRT, Chemotherapy, PD-1 antibody)

Recruiting
  • Radiotherapy
  • +3 more
  • SBRT
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 2, 2023

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023

Clinical Research of Drug Holiday Based on MRD Detection in GIST

Recruiting
  • Gastrointestinal Stromal Tumors
    • Beijing, Beijing, China
      Peking University People's Hospital
    May 11, 2023

    Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

    Recruiting
    • Durvalumab
    • +2 more
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Jan 3, 2023

    Prostate Cancer, Biochemical Recurrence, High Risk Trial in Nanjing, Nantong (Apalutamide 60mg Tab, Androgen deprivation

    Not yet recruiting
    • Prostate Cancer
    • +2 more
    • Apalutamide 60mg Tab
    • Androgen deprivation therapy(ADT)
    • Nanjing, Jiangsu, China
    • +2 more
    Mar 17, 2023

    Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

    Recruiting
    • Leukemia, Myeloid, Acute
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Dec 27, 2022

    Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

    Recruiting
    • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Jan 4, 2023

    Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

    Not yet recruiting
    • Triple Negative Breast Cancer
    • Residual Disease
    • (no location specified)
    Nov 15, 2023

    Radiomic fEatures of Pancreas From Contrast Enhanced CT Image

    Not yet recruiting
    • Pancreatitis, Chronic
    • Radiomics Model
    • (no location specified)
    Mar 20, 2023

    Neuroblastoma, CNS Tumor, Sarcoma Trial in Columbus (Cabozantinib)

    Recruiting
    • Neuroblastoma
    • +2 more
    • Columbus, Ohio
      Nationwide Children's Hospital
    Dec 20, 2022

    Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Nov 10, 2022

    Improve Early Detection of Cancer Recurrence in High-Risk

    Recruiting
    • Stage III Melanoma
    • Stage IV Cutaneous Melanoma
      • Cleveland, Ohio
        Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
      Oct 6, 2022

      Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))

      Recruiting
      • Cholangiocarcinoma, Intrahepatic
      • Shanghai, China
        Lulu@Huashan.Org.Cn
      Aug 16, 2022

      Kidney Stone Trial in Montréal (Ure-Na)

      Withdrawn
      • Kidney Stone
      • Montréal, Quebec, Canada
        Centre Hospitalier de l'Université de Montréal (CHUM)
      Nov 22, 2022

      Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

      Recruiting
      • Gastrointestinal Stromal Tumors
      • Minimal Residual Disease
      • liquid biopsy
      • Beijing, Beijing, China
        Peking University People'S Hospital
      Sep 18, 2022

      NSCLC Trial (Icotinib)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • (no location specified)
      Aug 23, 2022

      Pancreatic Neuroendocrine Tumor G2 Trial (Octreotide LAR)

      Completed
      • Pancreatic Neuroendocrine Tumor G2
      • Octreotide LAR
      • (no location specified)
      Oct 17, 2023

      Intrahepatic Cholangiocarcinoma Trial in Hangzhou (Tislelizumab combined with GEMOX (GOT) regimen)

      Not yet recruiting
      • Intrahepatic Cholangiocarcinoma
      • Tislelizumab combined with GEMOX (GOT) regimen
      • Hangzhou, Zhejiang, China
        1# Banshan East Rd. Zhejiang cancer hospital
      Sep 24, 2022

      Hepatocellular Carcinoma Trial in Shanghai (lenvatinib, TACE)

      Active, not recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Huashan hospital
      Jul 29, 2022

      Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

      Active, not recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Anlotinib Hydrochloride
      • TACE
      • Lanzhou, Gansu, China
      • +3 more
      Jan 12, 2023

      Gastric Cancer Trial in Krakow (FLOT4 + HIPEC + Surgery, FLOT4 + Surgery)

      Recruiting
      • Gastric Cancer
      • FLOT + HIPEC + Surgery
      • FLOT + Surgery
      • Krakow, Lesser Poland Voivodship, Poland
        Department of General, Oncological, Gastroenterological Surgery
      Nov 9, 2022